<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03922451</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-P00030970</org_study_id>
    <nct_id>NCT03922451</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support</brief_title>
  <official_title>Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure plasma concentrations of piperacillin-tazobactam and cefazolin in
      pediatric patients supported with extracorporeal membrane oxygenation (ECMO) aiming to better
      understand the pharmacokinetics of these medications in this in vivo setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration: piperacillin-tazobactam</measure>
    <time_frame>Peri drug dose administration until cessation of antibiotic therapy or cessation of ECMO support up to a maximum of 4 weeks.</time_frame>
    <description>Drug levels will be checked at baseline followed by additional measurements after the dose based on the dosing intervals but anticipated to be 30, 60, 120, 360, 480 minutes after the dose. Dosing regime will be q8-12 hourly pending end organ function (at the discretion of the treating team). The study will be continued for the duration of the Antibiotic therapy whilst on ECMO support and for one set of samples following decannulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration: cefazolin</measure>
    <time_frame>Peri drug dose administration until cessation of antibiotic therapy or cessation of ECMO support up to a maximum of 4 weeks.</time_frame>
    <description>Drug levels will be checked at baseline followed by additional measurements after the dose based on the dosing intervals but anticipated to be 30, 60, 120, 360, 480 minutes after the dose. Dosing regime will be q8-12 hourly pending end organ function (at the discretion of the treating team). The study will be continued for the duration of the Antibiotic therapy whilst on ECMO support and for one set of samples following decannulation.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Drug Effect</condition>
  <arm_group>
    <arm_group_label>Pediatric patients supported on ECMO</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>piperacillin-tazobactam</intervention_name>
    <description>Administered for infection treatment or prophylaxis per hospital protocol</description>
    <arm_group_label>Pediatric patients supported on ECMO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>Administered for infection treatment or prophylaxis per hospital protocol</description>
    <arm_group_label>Pediatric patients supported on ECMO</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All pediatric patients who are supported on ECMO at Boston Children's Hospital Cardiac
        Intensive Care Unit (CICU) and receive piperacillin-tazobactam or cefazolin as part of
        routine care or infection management.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  supported on ECMO

          -  receive piperacillin-tazobactam or cefazolin as part of routine care or infection
             management

        Exclusion Criteria:

          -  &gt;= 18 years

          -  No Consent provided
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katie M Moynihan, MBBS</last_name>
    <phone>6177126121</phone>
    <email>katie.moynihan@cardio.chboston.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Viviane Nasr, MD</last_name>
    <phone>6173556225</phone>
    <email>Viviane.Nasr@childrens.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Moynihan, MBBS</last_name>
      <phone>617-712-6121</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Katie Moynihan</investigator_full_name>
    <investigator_title>Cardiac Intensivist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

